MajorAtypical antipsychotic – dibenzodiazepine×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
In the liver, CYP1A2 and CYP3A4 metabolise almost all of the clozapine, with some contribution from CYP2C19 and CYP2D6 (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Phenytoin is a strong inducer of the liver enzymes that metabolise drugs (phenytoin SmPC, AEMPS, section 4.5). The US Food and Drug Administration (FDA) classes it as a strong CYP3A4 inducer (US Clozaril label, FDA, section 7.1). When phenytoin is added to clozapine, clozapine levels can fall, and the treatment can become less effective (Spanish clozapine SmPC, AEMPS, section 4.5; US Dilantin label, FDA, section 7.2). After phenytoin is stopped, clozapine levels can rise, and so can the risk of adverse reactions (US Clozaril label, FDA, section 7.1). Clozapine can cause agranulocytosis (Spanish clozapine SmPC, AEMPS, section 4.4). Haematopoietic complications, including granulocytopenia, agranulocytosis and pancytopenia, sometimes fatal, have occasionally been reported with phenytoin (phenytoin SmPC, AEMPS, section 4.4).
Symptoms
Clozapine can become less effective, and psychotic symptoms can worsen (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). After phenytoin is stopped, clozapine levels can rise, and so can the risk of adverse reactions. These include seizures, whose risk depends on the clozapine dose (US Clozaril label, US Food and Drug Administration, FDA, sections 5.4 and 7.1). Signs of agranulocytosis include fever, sore throat, flu-like symptoms and any other sign of infection (Spanish clozapine SmPC, AEMPS, section 4.4).
Management
The US Food and Drug Administration (FDA) does not recommend taking clozapine with strong CYP3A4 inducers and names phenytoin among them (US Clozaril label, FDA, sections 2.7 and 7.1). If the combination cannot be avoided, the clozapine dose may need to be increased and its effectiveness monitored (US Clozaril label, FDA, section 2.7). If phenytoin has to be used, the patient is closely watched for worsening psychotic symptoms (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Starting or stopping phenytoin may require a change in the clozapine dose (US Dilantin label, FDA, section 7.2). After phenytoin is stopped, consider lowering the clozapine dose (US Clozaril label, FDA, section 7.1). If clozapine is used with another drug known to cause neutropenia, the FDA suggests considering more frequent absolute neutrophil count (ANC) monitoring than the standard schedule (US Clozaril label, FDA, section 5.1). Granulocytopenia and agranulocytosis have occasionally been reported with phenytoin (US Dilantin label, FDA, section 5.9). People with a history of epilepsy are closely observed during clozapine treatment because seizures with clozapine are dose-related. If seizures occur, the clozapine dose is reduced and, if needed, anticonvulsant treatment is started (Spanish clozapine SmPC, AEMPS, section 4.4). Clozapine is contraindicated in uncontrolled epilepsy (Spanish clozapine SmPC, AEMPS, section 4.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Dilantin (extended phenytoin sodium capsules) – prescribing information (2023)– FDA label, Viatris Specialty, DailyMed setid 86dd27d1-9cee-48ae-b55d-e2d2f7dbc593, version 3, 08/2023, section 7.2 (Drugs Affected by Phenytoin)
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Clozapina – Leponex (nº registro 59547), sección 4.5 (2026)– AEMPS, CIMA, nº registro 59547, revisión 06/2026, secciones 4.4 y 4.5
- FDA: Clozaril (clozapine) prescribing information (2025)– FDA, DailyMed, HLS Therapeutics, setid 90876802-0e3a-44c9-9ff7-1754dfbe736a, v21, 06/2025, sections 5.1, 5.4, 5.5, 7.1
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.3 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, sección 4.3
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.4 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, secciones 4.3 y 4.4
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), secciones 4.9 y 5.2 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos, Viatris), revisión 06/2026, secciones 4.9 y 5.2
- AEMPS: Ficha técnica: Fenitoína, Epanutin 100 mg (nº registro 45695), sección 4.4 (2024)– AEMPS, CIMA, nº registro 45695 (Epanutin 100 mg cápsulas duras, Viatris), revisión 01/2024 (texto revisado 09/2021), secciones 4.2, 4.4, 4.9 y 5.2